NZeno is a kiwi company aiming to supply pig kidneys suitable for human transplantation. The company is applying novel gene editing technology to unique high-health status New Zealand pigs whose kidneys would be more acceptable by the human body after surgery.
Behind this groundbreaking company are the renowned scientists who founded NZeno; Dr Paul Tan, Dr Olga Garkavenko and Professor Bob Elliott. This group are the pioneers of pig cell transplantation for the treatment of Diabetes and Parkinson’s disease. Each has a wealth of experience in this field and collectively form a unique combination to be able to progress this project.
Pig kidneys function in a similar manner to human kidneys. However, immune rejection prevents them from being transplanted into humans. Recent advancements in gene editing can inactivate genes responsible for immune rejection and potentially allow a transplanted pig kidney to function and restore human health.
NZeno has a unique herd of high health status pigs which originate from the remote sub-Antarctic Auckland Islands. Here they were isolated from other pig herds for two hundred years and maintained a pathogen free status. To date, these are the only pigs that have been approved for use as a source of cells in human transplantation.
Pacific Channel has been working with NZeno since the company’s inception and has invested in each capital raising round. NZeno has recently secured NZ$5m in its latest capital raise.
For more information on NZeno, please contact Pacific Channel or visit the company’s website here.